Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roberto Velez Bermudez

Emergency Medicine Caguas, PR Medical Doctor

NPI 1700087731 CMS profile 981462

Carr 172 Km 0.2, Caguas, PR 00726

Open in the dashboard

General payments

$1,666

37 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roberto Velez Bermudez of Caguas, PR is reported in the CMS Open Payments database as having received $1,666 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $100 1
2024 General $110 2
2023 General $270 4
2022 General $521 11
2021 General $21 1
2020 General $83 4
2019 General $562 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roberto Velez Bermudez
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Roberto Velez Bermudez were reported at $100. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Roberto Velez Bermudez Emergency Medicine median Middle half National median
2019 $562 $51 $18–$128 $163
2020 $83 $29 $16–$99 $114
2021 $21 $40 $18–$124 $132
2022 $521 $49 $20–$134 $149
2023 $270 $51 $22–$142 $160
2024 $110 $52 $22–$150 $164
2025 $100 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $693 18 payments
  2. Medtronic, Inc. $310 3 payments
  3. Inari Medical, Inc. $123 2 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $100 1 payment
  5. Boston Scientific Corporation $93 1 payment
  6. AstraZeneca Pharmaceuticals LP $82 4 payments
  7. Genentech USA, Inc. $81 1 payment
  8. Chiesi USA, Inc. $70 2 payments
  9. Gilead Sciences, Inc. $60 2 payments
  10. E.R. Squibb & Sons, L.L.C. $32 2 payments
  11. Other $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,666 37 payments
Products named General payments · program years 2019–2025
  1. XARELTO $693 18 payments
  2. FLOWTRIEVER CATHETER, S $123 2 payments
  3. CT THROMBECTOMY SYSTEM KIT $123 2 payments
  4. COREVALVE EVOLUT R $115 1 payment
  5. Consulta $100 1 payment
  6. LifeVest $100 1 payment
  7. SOLITAIRE X $95 1 payment
  8. WATCHMAN Access System $93 1 payment
  9. Xolair $81 1 payment
  10. CLEVIPREX $70 2 payments
  11. Other $163 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

274

Median for Emergency Medicine: 88

Drug cost

$2,012

Median for Emergency Medicine: $590

Branded share of claims

37.6%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 39 $666
Gabapentin Generic 45 $276
Prednisone Generic 42 $208
Ondansetron Odt Ondansetron Brand 24 $192
Ketorolac Tromethamine Generic 11 $185
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 40 $181
Famotidine Generic 43 $161
Azithromycin Generic 12 $90
Metoclopramide Hcl Generic 18 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xolair
  • Genentech USA, Inc. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record